(37 days)
Not Found
No
The document describes an automated system for microbial identification and susceptibility testing based on optical density, turbidity, and redox indicators. It does not mention any AI or ML components in its description or performance evaluation.
No
The device is an in vitro diagnostic (IVD) system used for identifying microorganisms and testing their susceptibility to antimicrobial agents. It provides information for healthcare professionals to guide treatment, but it does not directly treat or prevent a disease, nor does it affect the structure or function of the body.
Yes.
The device is intended for the rapid identification and in vitro antimicrobial susceptibility testing of bacterial isolates, which are diagnostic purposes for identifying pathogens and determining effective treatments.
No
The device description explicitly lists multiple hardware components (BD Phoenix instrument, panels, broths, indicator solution) in addition to software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the system is intended for "in vitro antimicrobial susceptibility testing of isolates from pure culture of most aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria of human origin." and "in vitro quantitative determination of antimicrobial susceptibility". The term "in vitro" is a key indicator of an IVD.
- Device Description: The description details a system that analyzes biological samples (bacterial isolates from pure culture) outside of the human body to provide information about their characteristics (identification and susceptibility to antimicrobial agents). This aligns with the definition of an IVD.
- Performance Studies: The performance studies described involve testing bacterial isolates and comparing the results to reference methods, which is typical for the validation of an IVD.
- Predicate Devices: The listed predicate devices are also automated microbiology systems used for identification and susceptibility testing, which are generally classified as IVDs.
Therefore, based on the provided information, the BD Phoenix™ Automated Microbiology System is clearly an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The BD Phoenix™ Automated Microbiology System is intended for the rapid identification and in vitro antimicrobial susceptibility testing of isolates from pure culture of most aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria of human origin.
The BD Phoenix™ Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus.
This premarket notification is for cefepime at concentrations of 0.5-64 ug/mL to Gram-negative ID/AST or AST only Phoenix panels with the removal of the limitations for Proteus species. Cefepime has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDAapproved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Enterobacter species
Escherichia coli
Klebsiella pneumoniae
Proteus mirabilis
Pseudomonas aeruginosa
Active In Vitro Against:
Acinetobacter lwoffi
Citrobacter koseri
Citrobacter freundii
Hafnia alvei
Klebsiella oxytoca
Morganella morganii
Pantoea agglomerans
Proteus vulgaris
Providencia rettgeri
Providencia stuartii
Serratia marcescens
Product codes (comma separated list FDA assigned to the subject device)
LON
Device Description
The BD Phoenix Automated Microbiology System (Phoenix System) is an automated system for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically relevant bacterial isolates. The system includes the following components:
- BD Phoenix instrument and software.
- BD Phoenix panels containing biochemicals for organism ID testing and antimicrobial agents . for AST determinations.
- BD Phoenix ID Broth used for performing ID tests and preparing AST Broth inoculum.
- BD Phoenix AST Broth used for performing AST tests only.
- BD Phoenix AST Indicator solution added to the AST Broth to aid in bacterial growth . determination.
The Phoenix AST method is a broth based microdilution test. The Phoenix system utilizes a redox indicator for the detection of organism growth in the presence of an antimicrobial agent. The Phoenix panel is a sealed and self-inoculating molded polystyrene tray with 136 micro-wells. Organisms for susceptibility testing must be a pure culture and preliminarily identified as a Gram-negative or Gram-positive isolate. Phoenix panels are inoculated with a specified organism density and placed in the instrument.
The instrument houses the panels where they are continuously incubated at a nominal temperature of 110. The readings are interpreted to give an identification of the isolate, minimum inhibitory concentration (MIC) values and category interpretations, S, I, or R (sensitive, intermediate, or resistant).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States. Phoenix System results for Challenge set isolates were compared to the expected results. Phoenix System results for clinical isolates were compared to the results obtained from the CLSI reference broth microdilution method.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The BD Phoenix™ Automated Microbiology System demonstrated substantially equivalent performance when compared with the CLSI (formerly NCCLS) reference broth microdilution method.
Site Reproducibility: Intra- and inter-site reproducibility of this antimicrobial agent in the BD Phoenix System was evaluated at three sites using a panel of Gram-negative isolates. Each site tested the isolates in triplicate on three different days using one lot of Gram-negative Phoenix panels containing this antimicrobial agent and associated reagents. The results of the study demonstrate for this antimicrobial agent there was an overall intra-site reproducibility of greater than 90% and an overall inter-site reproducibility greater than 95% for the gram-negative isolates tested.
Clinical Studies: Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States to demonstrate the performance of the Phoenix antimicrobial susceptibility test with the Gram-negative Phoenix panel format containing this antimicrobial agent. Essential Agreement (EA) and Category Agreement (CA) to expected/reference results for all isolates tested were calculated.
Table 1: Performance of BD Phoenix System for Gram-Negative Organisms by Drug
Antimicrobial: Cefepime
Concentration: 0.5-64 µg/mL
EA (n): 1384
EA (%): 98.0
CA (n): 1384
CA (%): 96.7
Accuracy: Reproducibility was 95% or greater within ± 1 dilution.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement (EA) occurs when the BD Phoenix™ Automated Microbiology System agrees exactly or within + one two-fold dilution to the reference result. Category Agreement (CA) occurs when the BD Phoenix™ Automated Microbiology System agrees with the reference method with respect to the FDA categorical interpretive criteria (susceptible, intermediate, and resistant).
For Cefepime:
EA: 98.0%
CA: 96.7%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K020321, K020323, K020322, K032675, K060444
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
510(K) SUMMARY
iCC-330/
| SUBMITTED BY: | Becton, Dickinson and Company
7 Loveton Circle
Sparks, MD 21152
Phone: 410-316-4938
Fax: (410)-316-4499 | DEC - 8 2006 |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| CONTACT NAME: | Janine Matlak
Regulatory Affairs Specialist | |
| DATE PREPARED: | October 31, 2006 | |
| DEVICE TRADE NAME: | BD Phoenix™ Automated Microbiology System -
Cefepime 0.5-64 μg/mL | |
| DEVICE COMMON NAME: | Antimicrobial susceptibility test system-short incubation | |
| DEVICE CLASSIFICATION: | Fully Automated Short-Term Incubation Cycle Antimicrobial
Susceptibility Device, 21 CFR 866.1645 | |
| PREDICATE DEVICES: | VITEK® System (PMA No. N50510) and BD Phoenix™
Automated Microbiology System with Gatifloxacin (K020321,
May 23, 2002), Ofloxacin (K020323, April 14, 2002), and
Levofloxacin (K020322, March 27, 2002). | |
| INTENDED USE: | The BD Phoenix™ Automated Microbiology System is
intended for the rapid identification and in vitro antimicrobial
susceptibility testing of isolates from pure culture of most
aerobic and facultative anaerobic Gram-negative and Gram-
positive bacteria of human origin. | |
DEVICE DESCRIPTION:
The BD Phoenix Automated Microbiology System (Phoenix System) is an automated system for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically relevant bacterial isolates. The system includes the following components:
- BD Phoenix instrument and software. .
- BD Phoenix panels containing biochemicals for organism ID testing and antimicrobial agents . for AST determinations.
- BD Phoenix ID Broth used for performing ID tests and preparing AST Broth inoculum. .
- BD Phoenix AST Broth used for performing AST tests only. .
- BD Phoenix AST Indicator solution added to the AST Broth to aid in bacterial growth . determination.
1
The Phoenix AST method is a broth based microdilution test. The Phoenix system utilizes a redox indicator for the detection of organism growth in the presence of an antimicrobial agent. murculor for the detection of the indicator as well as bacterial turbidity are used in the determination Maasurements of enailyou to T panel configuration contains several antimicrobial agents with a wide range of two-fold doubling dilution concentrations.
The Phoenix panel is a sealed and self-inoculating molded polystyrene tray with 136 micro-wells The I nooms paired reagents. Organisms for susceptibility testing must be a pure culture and preliminarily identified as a Gram-negative or Gram-positive isolate. Phoenix panels are inoculated with a specified organism density and placed in the instrument.
The instrument houses the panels where they are continuously incubated at a nominal temperature of 110 mortalism now of the panels every 20 minutes. The readings are interpreted to give an identification of the isolate, minimum inhibitory concentration (MIC) values and category interpretations, S, I, or R (sensitive, intermediate, or resistant).
DEVICE COMPARISON:
The BD Phoenix™ Automated Microbiology System demonstrated substantially equivalent performance when compared with the CLSI (formerly NCCLS) reference broth microdilution method. This premarket notification provides data supporting the use of the BD Phoenix™ Automated Microbiology System Gram-negative ID/AST or AST only Phoenix panels with this antimicrobial agent.
SUMMARY OF SUBSTANTIAL EQUIVALENCE TESTING:
The BD Phoenix™ Automated Microbiology System has demonstrated substantially equivalent performance when compared to the CLSI reference broth microdilution method (AST panels personalises rding to CLSI M7). The system has been evaluated as defined in the FDA guidance document, "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA', February 5, 2003.
Site Reproducibility
Intra- and inter-site reproducibility of this antimicrobial agent in the BD Phoenix System was evaluated at three sites using a panel of Gram-negative isolates. Each site tested the isolates in triplicate on three different days using one lot of Gram-negative Phoenix panels containing this antimicrobial agent and associated reagents.
The results of the study demonstrate for the this antimicrobial agent there was an overall intra-site reproducibility of greater than 90% and an overall inter-site reproducibility greater than 95% for the gram-negative isolates tested.
2
Clinical Studies
Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States to demonstrate the performance of the Phoenix antimicrobial susceptibility test with the Gram-negative Phoenix panel format containing this antimicrobial agent. Phoenix System results for Challenge set isolates were compared to the expected results. Phoenix System results for r linical isolates were compared to the results obtained from the CLSI reference broth microdilution method.
The performance of the Phoenix System was assessed by calculating Essential Agreement (EA) and Category Agreement (CA) to expected/reference results for all isolates tested. Essential Agreement (EA) occurs when the BD Phoenix™ Automated Microbiology System agrees exactly or within + one two-fold dilution to the reference result. Category Agreement (CA) occurs when the BD Phoenix™ Automated Microbiology System agrees with the reference method with respect to the FDA categorical interpretive criteria (susceptible, intermediate, and resistant).
Table 1 summarizes the performance for the isolates tested in this study.
Table 1: Performance of BD Phoenix System for Gram-Negative Organisms by Drug
| Antimicrobial
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | Concentration
And A . A
Company of Children to Children the Children of Children the Children | EA (n
TWY | 10/0
EA | CA (n) | CA
(0/0) |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|--------------|--------------------------------------|--------|-------------|
| range of the comments of
Cefepime | 0.5-64 µg/mL | 1384 | STATIST THE OWNER OF THE FOR
98.0 | 1384 | 96.7 |
Conclusions Drawn from Substantial Equivalence Studies
The data collected from the substantial equivalence studies demonstrate that testing on the BD Phoenix™ Automated Microbiology System with this antimicrobial agent is substantially equivalent as outlined in the FDA guidance document, "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", February 5, 2003. Technological characteristics of this system are substantially equivalent to those used in the VITEK® system, which received approval by the FDA under PMA number N50510 and BD Phoenix™ Automated Microbiology System with Gatifloxacin (K020321, May 23, 2002), and Cefepime (K032675, March 1, 2004 and K060444, April 12, 2006).
3
SUMMARY INFORMATION FOR CEFEPIME Available Range 0.5-64 µg/mL
Performance
Accuracy
| Carline Corporation Come Comment
And Address of Canada Children Company Come of Children Company Come of Children Company Come of Children Company Come of Children Company Come of Children Comments of Childr
Antimicrobia
ССРОСТОВСКОГО СПОДНИКА АВТО | STATIST SULFILER LEASE S.
Concentration | A 400 A . AND A . CARD A . Canada Cases . Canada . Canada . Canada . Canada . Canada . Ca
10-4 | THE FOR THE PERSONAL ALL CLAIM .
Property | Acres Acres of | Company Company of Art Children |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------|----------------|---------------------------------|
| t
efenime
N REE IN | 1.00 1 | (
1 Bar | of Personal A 16 | | ﮨﺎﺋ
ﺮ |
Reproducibility
Testing performed at multiple clinical sites demonstrated 95% reproducibility or greater within 士 1 dilution.
Breakpoints - CLSI, FDA
| Station and the continued and the comments of
Annual Property of Children Company of Children of Children of Children of
Sun March Associate (All of All Art
The Comments of Children Comments of
AND ALERSHIP A AND OR FOR COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGION COLLEGIO
A more of the comments of accession in
100 00 00 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
MAN ARRANT AND SERVICE A ALL PALL FOR E CLAIMS
.
100 000 11 00 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Company Colling Collins Collins Colline Company Contract Concess to Children Company Contract Concess to Children Company of the Charge Company of the Charge Come of the Char | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
A RAAG AS A MA
Assessment company of the considered and any of | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ANNO : ANNELO : A MALES : CLANDA : COLORIAL : COLORIAL : COLLECTION : COLLECTION : COLLECTION : COLLECTION : COLLECTION : COLLECTION : COLLECTION : COLLECTION : COLLECTION : | A CONSULERS CONSULT & A CELESS OF A COLLECTION OF COLLECTION OF COLLECTION OF COLLECTION OF COLLECTION OF COLLECTION OF COLLECTION OF COLLECTION OF CONSULTION OF CONSULTION O
Company of the children the contraction of the contraction of the consideration of the consideration of the consideration of the consideration of the consideration of the con
No. of Canadian Company of the Research of the Research of the Real Property of the Real Property of the Real Property of the Real Property of the Real Property of the Real P
Children Children Children Children Courts of |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N MALE ME T LINE
| 1 80 1 8 80 10 1 |
|---|
| 100 A 10000 AND COLLECT CO. |
| l |
| I |
| LAND IL CL CLASS AND AND LEASE LABORATE |
| seudomonas aeruginosa |
| A 11 11 |
-
| BARRAND | CALL PROPERTIE RE 11 - 8 8 1 800 MENT 8 SURNEL 1 1 80 8
CHAND AND & Chicago Co.
1 |
Recommended Quality Control Organisms
| Quality Control Strain | MIC Range | Source |
|---|---|---|
| Escherichia coli ATCC 25922 | 0.015-0.12 µg/mL | CLSI |
| 0.016-0.12 µg/mL | FDA | |
| Pseudomonas aeruginosa ATCC 27853 | 1.0-8.0 µg/mL | CLSI |
| 1.0-4.0 µg/mL | FDA |
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three curved lines representing its wings or feathers. The eagle faces to the right. Encircling the eagle is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Janine Matlak Regulatory Affairs Specialist BD Diagnostics Systems Becton, Dickinson and Company 7 Loveton Circle Sparks, MD 21152
DEC - 8 2006
Re: K063301 Trade/Device Name: BD Phoenix™ Automated Microbiology System Cefepime (0.5-64 µg/mL) -- Gram-Negative ID/AST or AST Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices Regulatory Class: Class II Product Code: LON Dated: October 31, 2006 Received: November 1, 2006
Dear Ms. Matlak:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
5
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally, anton
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Page 1 of 1
510(k) Number: LDU3301
Device Name: BD Phoenix™ Automated Microbiology System for use with the antimicrobial agent cefepine (0.5-64 µg/mL) - Gram-Negative ID/AST or AST only Phoenix panels with the removal of the limitations for Proteus species.
Indications for Use:
The BD Phoenix™ Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus.
This premarket notification is for cefepime at concentrations of 0.5-64 ug/mL to Gram-negative ID/AST or AST only Phoenix panels with the removal of the limitations for Proteus species. Cefepime has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDAapproved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
| Enterobacter species | Proteus mirabilis |
|---|---|
| Escherichia coli | Pseudomonas aeruginosa |
| Klebsiella pneumoniae |
Active In Vitro Against:
Acinetobacter lwoffi Citrobacter koseri Citrobacter freundii Hafnia alvei
Prescription Use イ (Per 21 CFR 801.109)
Klebsiella oxytoca Morganella morganii Pantoea agglomerans Proteus vulgaris
Providencia rettgeri Providencia stuartii Serratia marcescens
Over-the-Counter Use
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
BD Diagnostic Systems
Becton, Dickinson and Company
K06 3301